Retatrutide vs Tirzepatide: Receptor Pharmacology and Clinical Research Compared

How retatrutide and tirzepatide differ in receptor targets, molecular design and published trial evidence. Laboratory reference only.

By Updated

Retatrutide and tirzepatide come from the same laboratory and the same design programme, and the difference between them can be stated in one line: tirzepatide activates two receptors, retatrutide activates three. Everything else on this page follows from that, including the parts where the literature cannot answer the question being asked of it.

This page compares published pharmacology and published research. It does not rank the two compounds, it does not name a better one, and it contains no guidance of any kind on handling either material. Where the two have never been studied against each other, that is stated rather than papered over with numbers from separate trials.

What they are

PropertyRetatrutideTirzepatide
Development codeLY3437943LY3298176
Compound typeSynthetic modified peptideSynthetic modified peptide
Peptide familyGlucagon / secretin peptide superfamily (GIP, GLP-1 and glucagon receptor ligands)Glucagon / secretin peptide superfamily (GIP and GLP-1 receptor ligands)
Primary targetGlucose-dependent insulinotropic polypeptide receptor (GIPR)Glucose-dependent insulinotropic polypeptide receptor (GIPR)
Secondary targetsGlucagon-like peptide-1 receptor (GLP-1R), Glucagon receptor (GCGR)Glucagon-like peptide-1 receptor (GLP-1R)
Receptor familyClass B1 (secretin-like) G protein-coupled receptorsClass B1 (secretin-like) G protein-coupled receptors
Agonist / antagonistAgonist at all three receptorsAgonist at both receptors
Highest research phasePhase 3 (completed and reported)Approved; phase 3 programmes and a cardiovascular outcome trial completed and reported
Regulatory status (United States)Not approved. Retatrutide is an investigational compound and has not been approved by the U.S. Food and Drug Administration for any indication.Approved as a finished pharmaceutical product. Tirzepatide is the active ingredient of products approved by the U.S. Food and Drug Administration and marketed by Eli Lilly and Company. That approval attaches to those finished products as manufactured, formulated and labelled by their sponsor. It does not attach to tirzepatide as a chemical, and it confers nothing on research-grade material supplied for laboratory use.
Human trials publishedYesYes

Every value in this table is read from the two compounds’ own library entries when the site is built, so it cannot disagree with them. Nothing here ranks one compound against the other.

Tirzepatide is a synthetic 39-residue peptide developed by Eli Lilly and Company under the code LY3298176, first described in 2018 as a dual agonist at the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor [1]. It has completed a large phase 3 programme and is an approved medicine in the United States in defined indications.

Retatrutide is a synthetic 39-residue peptide from the same sponsor, developed under the code LY3437943 and first described in 2022. It adds a third receptor — the glucagon receptor — to the two that tirzepatide engages [2]. It is investigational and has not been approved by the U.S. Food and Drug Administration for any indication.

Both are built on the same structural template, which is why they are so often set beside each other. Both are modified peptides of the glucagon–secretin superfamily; both are stabilised against dipeptidyl peptidase-4, the enzyme that clears native incretins within minutes; and both carry a fatty acid attached to a lysine side chain, which binds the molecule reversibly to serum albumin and converts a plasma half-life measured in minutes into one measured in days [1, 2]. That shared chemistry is why both are studied on a once-weekly schedule.

The approval status is the single most consequential difference between them and it is not a pharmacological one. Approval in the United States attaches to a specific compound for a specific indication. Tirzepatide having it confers nothing at all on retatrutide, and nothing in this comparison should be read as if it did.

Receptor and mechanistic differences

All three receptors at issue — GIPR, GLP-1R and GCGR — belong to the class B1, or secretin-like, family of G protein-coupled receptors, and all three couple through Gs to raise intracellular cyclic AMP [1, 2]. So the mechanistic difference between the two compounds is not a difference of signalling chemistry. It is a difference of which tissues are engaged.

The GIP and GLP-1 receptor arms are shared. Both receptors are expressed on pancreatic islet cells and in regions of the central nervous system, and their activation modulates glucose-dependent insulin secretion and reduces calorie intake. Tirzepatide engages exactly these two, and its published design rationale is that the GIP arm contributes something the GLP-1 arm does not — including better gastrointestinal tolerability at a given level of GLP-1 receptor engagement [1].

The glucagon receptor arm is what retatrutide adds, and it is a genuine departure rather than a third increment of the same thing. Glucagon receptor signalling in liver and adipose tissue raises whole-body metabolic rate. Historically this was the reason glucagon agonism was avoided in diabetes research altogether, since unopposed glucagon action raises blood glucose. The design premise reported for retatrutide is that the two incretin arms hold glucose in check while the glucagon arm contributes a separate route to metabolic change, so that the glycaemic liability of glucagon agonism is offset inside the same molecule [2].

A second, subtler difference is the balance between arms. In a multi-agonist the relative potency at each receptor is a tunable design parameter, and it distinguishes one molecule from another far more than the backbone sequence does. Tirzepatide is reported as an imbalanced dual agonist with greater relative activity at GIPR than at GLP-1R [1]. Retatrutide is reported as balanced between GCGR and GLP-1R with relatively greater activity at GIPR [2]. These are characterisations of cell-based assay behaviour, not predictions of anything in a person.

Receptors engaged
Tirzepatide — GIPR and GLP-1R. Retatrutide — GIPR, GLP-1R and GCGR [1, 2].
Receptor family
Both act only at class B1 G protein-coupled receptors, all Gs-coupled [1, 2].
Reported relative potency
Tirzepatide, greater at GIPR than GLP-1R. Retatrutide, balanced at GCGR and GLP-1R with greater activity at GIPR [1, 2].
Half-life strategy
Both use fatty-acid acylation and albumin binding to reach a once-weekly plasma half-life; the reported half-life is approximately five days for tirzepatide and approximately six days for retatrutide [1, 3].
Regulatory position
Tirzepatide is approved in the United States in defined indications. Retatrutide is not approved for anything.

What the research compares

This is the section where an honest comparison page has to say what it cannot do.

There is no head-to-head trial of retatrutide against tirzepatide. No registered study has randomised participants between the two compounds, and none of the published retatrutide trials carries tirzepatide as an active comparator. The retatrutide phase 2 trial in type 2 diabetes used dulaglutide 1.5 mg as its active comparator, not tirzepatide [8]; the phase 2 obesity trial and the phase 3 monotherapy trial were placebo-controlled [7, 14]. On the tirzepatide side, the two head-to-head trials that exist compared tirzepatide with semaglutide, not with retatrutide [5, 12].

What that means in practice is that the only way to set a retatrutide number beside a tirzepatide number is to lift the two out of separate trials — and the differences between those trials are large enough that the exercise produces an artefact rather than a comparison. The trials differ in duration, in the populations enrolled, in whether the comparator was placebo or an active drug, in whether diabetes was an inclusion or an exclusion criterion, and in the escalation schedules used. A 48-week figure and a 72-week figure are not two measurements of the same thing.

The sections below therefore report what each compound's own literature says, tiered by the kind of evidence it is, and stop short of subtracting one from the other. Cross-trial comparison of incretin compounds has been attempted systematically, and the published analyses of approved incretin mimetics are explicit that indirect comparison across placebo-controlled trials carries assumptions that head-to-head randomisation does not require [18].

What the human research shows for each

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

Tirzepatide — the completed programme

The SURPASS trials covered type 2 diabetes. SURPASS-1 randomised 478 adults with type 2 diabetes inadequately controlled by diet and exercise alone; mean glycated haemoglobin fell by 1.87% to 2.07% across the three groups against +0.04% for placebo at 40 weeks, and body-mass reduction ranged from 7.0 to 9.5 kg [4]. SURPASS-CVOT then tested cardiovascular outcomes in 13,299 participants with type 2 diabetes and atherosclerotic cardiovascular disease against dulaglutide 1.5 mg: the primary composite occurred in 12.2% against 13.1%, hazard ratio 0.92, meeting noninferiority but not superiority [13].

The SURMOUNT trials covered obesity. SURMOUNT-1 randomised 2,539 adults without diabetes; mean percentage change in body mass at week 72 was −15.0%, −19.5% and −20.9% across the three groups against −3.1% for placebo [6]. Separate phase 3 work reported change in the apnoea-hypopnoea index in participants with moderate-to-severe obstructive sleep apnoea and obesity, and phase 2 work reported histological endpoints in metabolic dysfunction-associated steatohepatitis [10, 9].

Retatrutide — the programme in progress

Retatrutide's published clinical record is shorter and its phase 3 programme newer. The phase 1b trial in 72 adults with type 2 diabetes reported a plasma half-life near six days and placebo-adjusted glycated haemoglobin reductions of 1.2% to 1.6% in the three highest groups at 12 weeks [3]. The phase 2 obesity trial randomised 338 adults and reported least-squares mean change in body weight at 48 weeks of −8.7%, −17.1%, −22.8% and −24.2% across the groups against −2.1% for placebo [7]. The phase 2 trial in type 2 diabetes randomised 281 adults against both placebo and dulaglutide 1.5 mg, and reported glycated haemoglobin change at 24 weeks ranging from −0.43% to −2.02% against −0.01% for placebo and −1.41% for dulaglutide [8].

A phase 2a substudy in 98 participants with metabolic dysfunction-associated steatotic liver disease reported mean relative change in liver fat at 24 weeks of −42.9% to −82.4% across the groups against +0.3% for placebo [11]. The first phase 3 result, TRANSCEND-T2D-1, randomised 537 adults with type 2 diabetes and reported mean glycated haemoglobin change of −1.69% to −1.94% against −0.81% for placebo at 40 weeks [14, 19]. The TRIUMPH registrational trials in obesity have completed their primary phases [15, 20].

Why these two sets of numbers do not subtract

The figures above are grouped by compound on purpose. SURMOUNT-1 ran 72 weeks in participants without diabetes against placebo; the retatrutide phase 2 obesity trial ran 48 weeks in a partly overlapping population against placebo, and was powered to characterise the relationship between the amount administered and the response rather than to establish a maximum. SURPASS-CVOT enrolled 13,299 participants against an active comparator; TRANSCEND-T2D-1 enrolled 537 against placebo in a population with a mean diabetes duration of 2.5 years. Adverse-event profiles are also reported against different denominators and different escalation schedules, so the gastrointestinal event rates in the two programmes are not directly comparable either.

The one structural point that can be made across both is that gastrointestinal events dominate the adverse-event reporting in every trial of both compounds, are mostly mild to moderate, cluster during escalation, and are the leading cause of discontinuation [6, 7, 14].

What the preclinical research shows

Animal research

The rodent work is where the third receptor arm was actually isolated, and it is the clearest illustration of why a tri-agonist is not simply a stronger dual agonist.

In diet-induced obese mice, retatrutide reduced body mass and improved glycaemic control, and the authors separate the effect into two contributions: a reduction in calorie intake attributable to the GIP and GLP-1 receptor arms, and an increase in whole-body metabolic rate attributable to the glucagon receptor arm, added on top [2]. That decomposition is the mechanistic claim the entire tri-agonist programme rests on, and it was demonstrated in mice years before any phase 3 human result existed.

The rodent literature on triple agonism is older than retatrutide itself. A rationally designed monomeric triagonist at the same three receptors was reported in 2015 and characterised in rodent obesity and diabetes models [16], and later work compared successive generations of GLP-1/GIP/glucagon triple agonists in obese mice [17]. Tirzepatide's own rodent characterisation accompanied its discovery paper [1].

Diet-induced obesity models in rodents are a standard preclinical tool and a poor predictor of human results in this field specifically. Findings described in this section were observed in animals. Nothing in them establishes anything about humans, and nothing in them establishes anything about the other compound on this page.

Where the in vitro pharmacology differs

In vitro research

The cell-based assays are the only place the two molecules have been characterised on something approaching a common measure, because both discovery papers report activity at cloned human receptors expressed in cell lines.

Tirzepatide was characterised as an imbalanced dual agonist, with activity at the GIP receptor comparable to native GIP and weaker relative activity at the GLP-1 receptor than native GLP-1 [1]. Retatrutide was characterised as balanced between the glucagon and GLP-1 receptors with relatively greater activity at the GIP receptor [2].

Two cautions apply before those two sentences are set against each other. First, they come from different papers, different assay formats and different reference standards, so the numbers are not interchangeable even though the receptors are the same. Second, in vitro potency at a cloned receptor in a transfected cell line does not translate into a proportional effect in tissue, let alone in a person — the receptors in question sit in different organs at different densities, and the albumin binding that gives both molecules their half-life is absent from the assay entirely.

Research status of each

Tirzepatide has completed a large phase 3 programme across type 2 diabetes, obesity, a respiratory indication described in the human-clinical section above, and cardiovascular outcomes, and is an approved medicine in the United States in defined indications [4, 6, 10, 13].

Retatrutide remains investigational. Its phase 3 programme has begun reporting — TRANSCEND-T2D-1 in type 2 diabetes [14] and the TRIUMPH registrational trials in obesity, which have completed their primary phases [15] — but no approval exists for any indication, in the United States or elsewhere.

Both are pharmaceutical development programmes conducted by a sponsor under registered protocols, using investigational material manufactured to a regulatory standard, administered under clinical supervision in defined populations. None of that research is research into, or evidence about, research-grade material supplied for laboratory use, and the distinction is not a formality.

Frequently Asked Questions

What is the difference between retatrutide and tirzepatide?
The number of receptors each molecule activates. Tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor [1]. Retatrutide adds a third target, the glucagon receptor, to those two [2]. Both are 39-residue modified peptides from the same sponsor, both are stabilised against dipeptidyl peptidase-4, and both are acylated so that albumin binding gives them a plasma half-life measured in days.
Has retatrutide ever been compared with tirzepatide in a trial?
No. No registered study has randomised participants between the two compounds, and no published retatrutide trial carries tirzepatide as an active comparator. The retatrutide phase 2 trial in type 2 diabetes used dulaglutide 1.5 mg as its comparator [8], and the phase 2 obesity trial and the first phase 3 trial were placebo-controlled [7, 14]. Setting a figure from one programme beside a figure from the other produces an artefact of differing trial designs, not a comparison.
Which receptors does each compound target?
Tirzepatide targets GIPR and GLP-1R. Retatrutide targets GIPR, GLP-1R and GCGR [1, 2]. All three are class B1, or secretin-like, G protein-coupled receptors, and all three couple through Gs to raise intracellular cyclic AMP, so the difference between the two molecules is which tissues are engaged rather than which signalling chemistry is used.
Why does the glucagon receptor arm matter?
Glucagon receptor signalling in liver and adipose tissue raises whole-body metabolic rate, which is a route that incretin receptor agonism alone does not reach. It was historically avoided in diabetes research because unopposed glucagon action raises blood glucose. The reported design premise for retatrutide is that the two incretin arms hold glucose in check while the glucagon arm contributes separately, within one molecule [2]. In diet-induced obese mice that separation was demonstrated directly [2], but a finding in mice establishes nothing about humans.
Is either compound approved by the FDA?
Tirzepatide is an approved medicine in the United States in defined indications. Retatrutide is not approved for any indication, anywhere. Regulatory approval in the United States attaches to a specific compound for a specific indication, so approval of one compound confers nothing on another in the same pharmacological class, however similar the chemistry.
What research phase has each compound reached?
Tirzepatide has completed a large phase 3 programme spanning type 2 diabetes, obesity and cardiovascular outcomes [4, 6, 13]. Retatrutide's phase 3 programme has begun reporting: TRANSCEND-T2D-1 published in 2026 [14], and the TRIUMPH registrational trials have completed their primary phases [15].
Why can trial figures for the two compounds not simply be subtracted?
Because the trials differ in nearly every respect that determines the size of a result: duration, the population enrolled, whether the comparator was placebo or an active drug, whether diabetes was an inclusion or exclusion criterion, and the escalation schedule used. Published systematic analyses of approved incretin mimetics are explicit that indirect comparison across placebo-controlled trials rests on assumptions that head-to-head randomisation does not require [18].

References

  1. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Molecular Metabolism; 2018. PMID 30473097 doi:10.1016/j.molmet.2018.09.009
  2. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metabolism; 2022. PMID 35985340 doi:10.1016/j.cmet.2022.07.013
  3. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial The Lancet; 2022. PMID 36354040 doi:10.1016/S0140-6736(22)02033-5
  4. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial The Lancet; 2021. PMID 34186022 doi:10.1016/S0140-6736(21)01324-6
  5. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes The New England Journal of Medicine; 2021. PMID 34170647 doi:10.1056/NEJMoa2107519
  6. Tirzepatide Once Weekly for the Treatment of Obesity The New England Journal of Medicine; 2022. PMID 35658024 doi:10.1056/NEJMoa2206038
  7. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial The New England Journal of Medicine; 2023. PMID 37366315 doi:10.1056/NEJMoa2301972
  8. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA The Lancet; 2023. PMID 37385280 doi:10.1016/S0140-6736(23)01053-X
  9. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis The New England Journal of Medicine; 2024. PMID 38856224 doi:10.1056/NEJMoa2401943
  10. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity The New England Journal of Medicine; 2024. PMID 38912654 doi:10.1056/NEJMoa2404881
  11. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Nature Medicine; 2024. PMID 38858523 doi:10.1038/s41591-024-03018-2
  12. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England Journal of Medicine; 2025. PMID 40353578 doi:10.1056/NEJMoa2416394
  13. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England Journal of Medicine; 2025. PMID 41406444 doi:10.1056/NEJMoa2505928
  14. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial The Lancet; 2026. PMID 42250575 doi:10.1016/S0140-6736(26)00967-0
  15. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Diabetes, Obesity and Metabolism; 2026. PMID 41090431 doi:10.1111/dom.70209
  16. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents Nature Medicine; 2015. PMID 25485909 doi:10.1038/nm.3761
  17. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice Molecular Metabolism; 2022. PMID 35809773 doi:10.1016/j.molmet.2022.101533
  18. Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials Diabetes, Obesity and Metabolism; 2025. PMID 40212008 doi:10.1111/dom.16398
  19. Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise. NCT06354660
  20. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight. NCT05929066

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.